Cécile Sonntag

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 175 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2024 · 112 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau et al. · Clinical Microbiology and Infection · 2024 · 60 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 ⁺ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Thibaut Leguay, Marc Delord, Cyril Šálek et al. · Journal of Clinical Oncology · 2024 · 34 citations

Medicine, Hematology, Oncology +16